131 related articles for article (PubMed ID: 20553208)
21. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Bukowski RM
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842
[TBL] [Abstract][Full Text] [Related]
24. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD
Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
26. Bowel perforation after radiotherapy in a patient receiving sorafenib.
Peters NA; Richel DJ; Verhoeff JJ; Stalpers LJ
J Clin Oncol; 2008 May; 26(14):2405-6. PubMed ID: 18467733
[No Abstract] [Full Text] [Related]
27. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
30. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
[No Abstract] [Full Text] [Related]
31. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
32. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
33. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
34. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
35. [Clinical results of Nexavar for the treatment of kidney cancer].
Escudier B
Prog Urol; 2007 Feb; 17(1 Suppl 1):150-3. PubMed ID: 17571640
[No Abstract] [Full Text] [Related]
36. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Kamada P; Dudek AZ
Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944
[TBL] [Abstract][Full Text] [Related]
37. Evidence-based urology in practice: when to believe a subgroup analysis?
Wang SS; Ou YC; Cheng CL; Dahm P;
BJU Int; 2010 Jan; 105(2):162-4. PubMed ID: 19912181
[No Abstract] [Full Text] [Related]
38. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
39. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
40. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
Busse A; Asemissen AM; Nonnenmacher A; Braun F; Ochsenreither S; Stather D; Fusi A; Schmittel A; Miller K; Thiel E; Keilholz U
Eur J Cancer; 2011 Mar; 47(5):690-6. PubMed ID: 21215610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
